About Teclistamab
            
            Class: | Monoclonal antibody (bispecific T-cell engager)  
Use: | Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.  
Adult dose: | Initial dose of 1.5 mg/kg administered subcutaneously on Day 1, followed by 3 mg/kg on Day 8, and then 6 mg/kg on Day 15 and every subsequent week thereafter.  
Pediatric dose: | Safety and
         
        
            
                
                
                    
                        Drug Class
                    
                    Monoclonal antibody (bispecific T-cell engager)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: Janseen Cilag International, Belgium
                    
                    
                    Package Size
                    3mL Glass Vial
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 4744.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        Initial dose of 1.5 mg/kg administered subcutaneously on Day 1, followed by 3 mg/kg on Day 8, and then 6 mg/kg on Day 15 and every subsequent week thereafter.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy have not been established in pediatric patients; not recommended for use in this population.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include cytokine release syndrome (CRS), fatigue, nausea, diarrhea, anemia, thrombocytopenia, and neutropenia.
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to teclistamab or any component of the formulation; caution in patients with a history of severe CRS or neurological toxicities.
         
        
        
            
                Important Warnings
            
            Risk of severe or life-threatening CRS; monitor patients closely for signs and symptoms. Risk of neurological toxicities, including encephalopathy; consider discontinuation if severe symptoms occur.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.